NCT01929200 - Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

August 31, 2017

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG

1-year treatment with icotinib

Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.

DRUG

2-year treatment with icotinib

Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.

Trial Locations (1)

RECRUITING

Beijing Cancer hospital, Beijing